Revolution’s Rasonque off to best cancer drug launch ‘in history’
Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.
Revolution Medicines reported that its pancreatic cancer drug, Rasonque, generated $198 million in sales within five weeks of its U.S. approval. According to STAT News, more than 5,000 patients have been treated with the pan-RAS inhibitor. The sales performance was nearly double the most optimistic investor estimates prior to the company's third-quarter earnings announcement.
While STAT News described the commercial debut as eye-popping, Revolution Chief Commercial Officer Anthony Mancini stated during an earnings call that the U.S. launch is off to a strong start. BioPharma Dive reports that Wall Street analysts are resetting projections for the drug, though company executives cautioned that it is too early to draw conclusions regarding its launch trajectory.
Brief written by urgent.news from BioPharma Dive, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
